anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Emerging evidence indicates that more nuanced models of posttraumatic stress disorder (PTSD) may better capture the condition's symptom structure. Recent theoretical and empirical work suggest that an 8-factor model of PTSD with separate internally- (e.g. flashbacks) and externally- (e.g. trauma-cue related physiological reactivity) generated intrusive symptom clusters may advance understanding of PTSD and its treatment and course. However, the model's functional and clinical significance still requires evaluation. To this end, we analyzed data from the National Health and Resilience in Veterans Study, a nationally representative sample of 3847 trauma-exposed U.S. military veterans. Multivariable regressions were performed to assess the relationship between the 8 PTSD symptom clusters, assessed using the PTSD Checklist for DSM-5, and clinical and functional measures. Results revealed that externally-generated intrusions were associated with higher odds of current depression and anxiety and worse mental, cognitive, and psychosocial functioning. Anhedonia (e.g., loss of interest in enjoyable activities) symptoms were associated with all the correlates tested, while negative affect (e.g., having strong negative feelings such as fear) symptoms were associated with all measures except depression. Avoidance symptoms were associated with lower odds of current anxiety while externalizing behavior symptoms were linked to higher odds of suicidal ideation. Anxious arousal symptoms were associated with lower odds of suicidal ideation but higher odds of PTSD-related impairment/distress, while dysphoric arousal symptoms were associated with higher odds of current depression, PTSD-related impairment/distress and worse mental and cognitive functioning. Results suggest that a more nuanced 8-factor model of PTSD symptoms may help inform understanding of the clinical and functional correlates of this multi-faceted disorder.
Klotho, an anti-aging protein, has gained attention for its protective effects against various diseases, including metabolic disorders, through recombinant Klotho administration. However, the potential of Klotho as a target for gene therapy requires further exploration, as it remains relatively understudied in the context of metabolic disorders. In this study, we demonstrate that AAV-full length(FL)-Klotho administration induces weight loss in mice and provides protection against high-fat diet (HFD)-induced obesity and hepatic steatosis, concurrently reducing the weights of white adipose tissue and liver. AAV-FL-Klotho administration also enhanced thermogenic gene expression in brown adipose tissue (BAT) and improved the morphology of interscapular BAT. The weight loss effect of AAV-FL-Klotho was found to be, at least in part, mediated by UCP1-dependent thermogenesis in brown adipocytes, potentially influenced by hepatokines secreted from AAV-FL-Klotho-transduced hepatocytes. These findings suggest that AAV-FL-Klotho is an attractive candidate for gene therapy to combat obesity. Nevertheless, unbiased experiments have also revealed disturbances in lipid metabolism due to AAV-FL-Klotho, as evidenced by the emergence of lipomas and increased expression of hepatic lipogenic proteins.
This study is designed with two aims: Aim 1a: To explore differences in sleep health between older HIV+ AA and Whites. 1b: To explore differences in domain-specific neurocognitive impairments between older HIV+ AA and Whites. Aim 2a: To explore the relationship between sleep health and neurocognitive function. 2b: To explore the relationship between sleep health and cART adherence. 2c: To explore mediation effects of cART adherence between sleep health and neurocognitive function. This is the first study to explore racial disparities in sleep health and neurocognitive function, using EEG/ERP metrics, among older HIV+ adults. There are two phases in this study: Phase I which consists of neurocognitive testing and sleep assessments with actigraphy, and Phase II which consist of a 20-30 min EEG. Measurements of electrical brain activity will be captured while participants engage in an Attention Network Test which measures executive function, attention, and speed of processing.
Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
Exfoliating body soap cleanses and removes oils and particulates from the user's skin. The exfoliating body soap includes a cleansing surfactant base, a first quantity of exfoliating agent, and a second quantity of exfoliating agent. The cleansing surfactant base emulsifies and binds water insoluble oils and particulates present on a user's skin to be washed away using water. The first quantity of exfoliating agent and the second quantity of exfoliating agent are an abrasive material which exfoliates the user's skin, removing dead skin while exposing newer layers of skin. The first quantity of exfoliating agent is dispersed throughout the cleansing surfactant base. The second quantity of exfoliating agent is concentrated on an external surface of the cleansing surfactant base. This arrangement allows the user to have a consistent abrasiveness throughout the exfoliating body soap and a concentrated portion which the user can focus the abrasiveness of the exfoliating body soap.
HUMALOG may be administered by continuous subcutaneous infusion by an external insulin pump. Do not use diluted or mixed insulins in external insulin pumps. Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)]. Change the HUMALOG in the reservoir at least every 7 days, change the infusion sets and the infusion set insertion site at least every 3 days. 

The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Although there is significant variability among patients, approximately 50% of the total dose is usually given as meal-related boluses of HUMALOG and the remainder is given as a basal infusion. HUMALOG is recommended for use in pump systems suitable for insulin infusion such as MiniMed, Disetronic, and other equivalent pumps [see For Patients Using Continuous Subcutaneous Insulin Pumps (17.2)].
People with arthrosis of the shoulder joint will be treated using the traditional intervention, which includes physical therapy. The ultrasound imaging will be collected before the intervention and at 3-month. The imaging data will be used to build a imaging model using the machine learning method.
OBJECTIVE: Breast angiosarcoma is a tumor that can arise as a primary breast tumor or in association with prior radiation therapy. Angiosarcomas are uniquely sensitive to paclitaxel. This study evaluated the impact neoadjuvant paclitaxel (NAC) therapy has on surgical outcomes, tumor recurrence, and survival in breast angiosarcomas.
METHODS: Patients with angiosarcoma of the breast, either primary or radiation-associated, were identified from a prospective institutional database. Patients receiving NAC were compared to those treated with upfront surgery. Clinical and pathological variables were compared using Student's t-test or Fisher's exact test, differences in survival were calculated using Kaplan-Meier methods.
RESULTS: Twenty-four patients with angiosarcoma of the breast were identified, 10 with primary angiosarcoma and 14 with radiation-associated angiosarcoma. Twelve patients received NAC, 6 of each with primary angiosarcoma or radiation-associated angiosarcoma. Of these 12 patients, 11 had a margin negative resection (91%) of which, nine had a complete pathological response on surgical pathology. Of the 12 surgery-first patients, four (n = 4/12, 33%) had positive surgical margins, two of the four underwent reoperation. With a median follow-up of 16 months, four NAC patients had recurrence (33%) compared to six patients in the surgery-first group (58%) (p = 0.41). While not statistically significant, NAC patients had a 33% less risk of recurring compared to surgery-first patients ([hazard ratio =0.67 (95% confidence interval 0.16-2.72; p = 0.6]).
CONCLUSION: NAC for breast angiosarcoma may be associated with high rates of complete pathological response and margin-negative resection. However, this did not impact overall survival. Future prospective control studies and longer follow-up periods are warranted to understand the impact on recurrence and survival.
PURPOSE: To obtain an aqueous permanent wave liquid having a high curling efficacy in mild conditions and enabling true acidic permanent waves by adding a 1,3-alkanediol to a permanent wave liquid containing a compound effective for cutting disulfide bonds between the proteins of hair. CONSTITUTION: This permanent wave liquid contains at least one compound for cutting disulfide bonds between the proteins of hair. Therein, at least one biologically adaptable 1,3-alkanediol (e.g. a 2-alkyl-1,3-alkanediol, a 1,3- alkanediol) is added. More preferably, 2-7wt.% of 2-ethyl-1,3-hexanediol, etc., is added to a general permanent wave liquid. The composition can form permanent waves on hair in five minutes.
FIELD: medicine.SUBSTANCE: group of inventions refers to a nanoemulsion for active agent delivery, a method for preparing it, compositions containing it, and to using a nanoemulsion for preparing pharmaceutical compositions for local application and cosmetic compositions for skin application. The declared nanoemulstion contains a water ingredient and a carrier which contains a lipophilic ingredient in the amount of 0.1-15 wt %, a surfactant and isopropyl and/or 1-propyl alcohol. The average emulsified particle diameter makes less than 100 nm. The method for preparing the nanoemulsion involves mixing the water ingredient and carrier containing the lipophilic ingredient, surfactant and isopropyl and/or 1-propyl alcohol, for preparing the nanoemulsion at temperature 50-60°C. The invention also refers to the composition for photodynamic therapy containing the above nanoemulsion and the active agent representing 5-aminolevulinic acid, a derivative, a precursor and/or a metabolite thereof. The above composition is applied to prepare the drug substance for photodynamic therapy and to treat senile keratosis. What is also declared is a diagnostic composition for detecting the dividing cells which contains the nanoemulsion and 5-aminolevulinic acid. The invention also refers to a kit for photodynamic therapy which comprises the composition for photodynamic therapy and one ingredient specified in a photoresist coating, an agent for attaching the above coating or an agent for applying the composition.EFFECT: invention provides better stability and intensified cell and tissue penetration of the nanoemulsion.25 cl, 6 dwg, 9 tbl, 5 ex
PROBLEM TO BE SOLVED: To obtain an antimicrobial which shows a rapid antimicrobial rate with a small amount of application and is environmentally safe because it is rapidly decomposed after application by formulating specific dihaloformaldoxime carbamates as active ingredients. SOLUTION: This antimicrobial contains a dihaloformaldoxime carbamate (e.g. N-methyl-dibromoformaldoxime carbamate and the like) of the formula (X and Y are each Br and the like; R is an 1-8C alkyl and the like) as an active ingredient. The growth of organisms is inhibited by applying the above- mentioned antimicrobial in a concentration of 0.05-10000 ppm based on the volume of the object (e.g. cooling tower and air cleaner) to be attacked by organisms. Further, it is possible to use in combination with other antimicrobials (e.g. 5-chloro-2-methyl-4-isothiazolin-3-one and the like).
PURPOSE: A composition containing blueberry-fermented extract for preventing or treating obesity is provided to significantly reduce weight of organs and prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains blueberry-fermented extract as an active ingredient. A method for preparing the composition comprises: a step of fermenting blueberries using yeast and drying to obtain dried blueberry fermentation; and a step of dipping and extracting the dried blueberry fermentation using water, alcohol of C1-C4, or mixture solvent of C1-C4 alcohol. The yeast is Saccharomyces cerevisiae. The composition additionally contains pharmaceutically acceptable carrier. The carrier is saline solution, sterilized water, ringers solution, dextrose solution, malto dextrin solution, glycerol, ethanol, or mixture thereof.
AIM: To evaluate the microbial spectrum of urine before and after transurethral resection of prostate (TURP) in patients with postoperative infectious complications.
MATERIALS AND METHODS: A single-center retrospective observational study between 2016 and 2023 was carried out. Patients who developed urinary tract infections (UTIs) after mono- or bipolar TURP during the hospitalization were included. Bacteriological examination of urine obtained before procedure and after the manifestation of UTI was done in accordance with the Guidelines. In the presence of suprapubic or urethral catheter, the drainage was previously replaced with further microbiological study. The level of significant bacteriuria was more or equal 103 CFU/ml, with a level of significant leukocyturia more or equal 10 per field of view. Statistical analysis was carried out using IBM SPSS Statistics 23.0.
RESULTS: Bacteriuria was not detected in 77.9% of cases of UTIs after TURP. At the same time, according to the preoperative examination in 76.2% of these patients, there was no bacteriuria more or equal 103 CFU/ml. In 17 of 122 men (13.9%) without bacteriuria at baseline, microorganisms were isolated after the development of UTIs. A decrease in bacteriuria level was noted in only 19 of 29 patients (65.5%) who had a positive urine culture before TURP. Only in 4 out of 10 cases of persistent bacteriuria the same microorganism was isolated, while in the remaining 6 cases the initial spectrum was replaced by another bacteria.
CONCLUSION: Our data indicate a low detection rate of microorganisms in urine of patients with UTIs after TURP using a standard bacteriological study. The data indicate that the standard antibiotic prophylaxis regimen and ongoing anti-infective measures are partly effective in reducing a narrow range of aerobic microorganisms detected preoperatively using standard media, which, however, does not exclude the development of an infectious process.
PROBLEM TO BE SOLVED: To easily generate medicine instruction where medicine information required for an individual patient is described by storing individual medicine information of an assumed patient, inputting individual information of the patient with medicine information based on a formula and outputting medicine instruction where individual medicine information of the patient is mentioned. SOLUTION: An input device 9 inputs the content of the formula and individual information of the patient such as the age, the sex of the patient and the other taking medicine names. Thus, information corresponding to the content of the formula and individual information of the patient such as the age of the patient, which are previously stored in the storage device 11, are automatically selected. The input signals can easily be inputted to an input circuit 14. When the selection signals are inputted to the input circuit 14, a central processing unit 12 transmits an output signal selecting medicine information which requires output in medicine information stored in the storage device 11. A color printing machine 10 connected to the output circuit 18 prints medicine instruction.
BACKGROUND/AIMS: Upper gastrointestinal bleeding (UGIB) is a frequent medical issue. The primary risk factors for bleeding peptic ulcers are Helicobacter pylori infection and non-steroidal anti-inflammatory drugs. The association between acute gastric/duodenal ulcer and opium use has been previously proposed; however, there is no available data on endoscopic findings of patients with acute UGIB who use opium.
MATERIALS AND METHODS: In the present descriptive cross-sectional study, endoscopic data of 50 consecutive patients with oral opium use and 50 consecutive patients without any opium use who were admitted for UGIB were recorded. The size (5-10 mm, 11-20 mm, or more than 20 mm), number (single, double, or multiple), and location of the ulcers (esophagus, gastric corpus including the fundus and body, antrum, angulus, or duodenum) were examined by endoscopy in both groups.
RESULTS: Three or more ulcers were observed in 46% and 16% of patients with oral opium use and without opium use, respectively (P-value = 0.001). The rate of giant ulcers (> 20 mm) was significantly higher in patients who used oral opium (40% vs. 12%; P-value = 0.007). Esophageal ulcers were also more common in oral opium users (30%) than non-users (8%) with UGIB (P-value = 0.01). Nevertheless, the location of the ulcers between the two groups generally was not statistically different.
CONCLUSIONS: This study has demonstrated that multiple, large peptic ulcers in GIB are potential complications of oral opium use. This could aid the needed modifications in the treatment protocol for these patients.
This is a single center, 13-week, outpatient, randomized, double-blind, placebo-controlled, parallel group, pilot study of topiramate in subjects with Sleep-Related Eating Disorder (SRED). The primary objective of this study is to investigate the efficacy and safety of topiramate compared to placebo in the treatment of Sleep-Related Eating Disorder. SRED is a disorder that consists of out of control eating during the night with little or no awareness of the events. In this study we are comparing topiramate to placebo. A placebo is a pill that looks exactly like the study drug, but it does not have any active drug in it. Topamax (topiramate) is approved by the U.S. Food and Drug Administration (FDA) as a therapy for epilepsy, but topiramate has not been approved by the FDA for SRED.
Lipidic compositions with superior characteristics for in vivo delivery of oligodeoxynucleotides (ODN) can easily and efficiently be made in the form of small multilamellar vesicles. The compositions contain a population of nucleic acid-containing lipid vesicles in a liquid carrier, and at least a portion of the lipid vesicles are small multilamellar vesicles. The small multilamellar vesicles are made from a lipid component including 20-30 mol % of an ionizable amino lipid such as DODAP, and a steric barrier lipid such as PEG-CerC14; and an oligodeoxynucleotide contained in the lumen or interlamellar spaces of the small multilamellar vesicles. The ODN and lipid components are preferably present in the small multilamellar vesicles in a mole ratio of from 0.15 to 0.25. The compositions of the invention can be made by preparing two solutions: a lipid mixture with 20-30 mol % of the ionizable amino lipid, the steric barrier lipid and additional lipid components selected from among neutral lipids and sterols in an ethanolic solvent; and a solution of oligodeoxynucleotide in an aqueous solvent having a pH at which the ionizable amino lipid is positively charged. The lipid mixture is added to the solution of oligodeoxynucleotide to form a mixture containing lipid vesicles which is then massed through a filter to produce sized lipid vesicles in a solution containing ethanol. The ethanol is then removed, for example by dialysis. Then, the pH of the solution surrounding the sized lipid vesicles is increased to reduce the net positive charge on the exterior of the sized lipid vesicles.
BACKGROUND: Non-randomised studies assessing intrarectal botulinum toxin type A (BoNTA) injections for faecal incontinence are promising. We aimed to evaluate the efficacy of BoNTA for the treatment of faecal incontinence in a randomised study.
METHODS: In this randomised, double-blind, placebo-controlled study, we included adult patients who had at least one urgency or faecal incontinence episode per week for at least 3 months and who had experienced a failure of conservative or surgical treatment from eight French specialist hospital units with the skills to manage patients with faecal incontinence. Patients were randomly assigned (1:1) by a central web form to receive intrarectal submucosal injections of either 200 units of BoNTA (Botox; Allergan, Irvine, CA, USA; BoNTA group) or an equivalent volume of saline (placebo group), stratified by Cleveland Clinic Severity scores (CCS score; ≥12 or <12). Patients, investigators, study site staff, and sponsor personnel were masked to treatment allocation up to the 6-month visit. The primary endpoint was the number of episodes of faecal incontinence and urgency per day assessed using 21-day patient bowel diaries 3 months after the treatment. The primary analysis was performed using a modified intention-to-treat (mITT) approach (ie, in all the randomised patients who had received a treatment) with adjustment for baseline faecal incontinence and urgency episodes. After the final data collection at 6 months after injections, patients were unmasked and offered the BoNTA treatment if they were in the placebo group (rescue therapy) without masking, with an additional 6 months of safety follow-up. This trial is registered with ClinicalTrials.gov, number NCT02414425.
FINDINGS: Between Nov 25, 2015, and Nov 25, 2020, we randomly assigned 200 patients to receive either BoNTA (n=100) or placebo (n=100) injections. Due to withdrawals before the injections, 96 patients were included in the BoNTA group and 95 patients were included in the placebo group (mITT analysis). The mean number of faecal incontinence and urgency episodes per day in the BoNTA group decreased from 1·9 (SD 2·2) at baseline to 0·8 (1·8) at 3 months after the injections, and from 1·4 (1·1) to 1·0 (1·0) in the placebo group, with a baseline-adjusted mean group difference at 3 months estimated at -0·51 (95% CI -0·80 to -0·21, p=0·0008). No serious treatment-related adverse events were reported in the trial. The most frequently reported non-serious adverse event (treatment related or not) following the BoNTA or placebo injections was constipation (reported in 68 [40%] of 169 patients who received the BoNTA injections and 38 [40%] of 95 patients who received placebo injections).
INTERPRETATION: BoNTA injections are an efficacious treatment for urge faecal incontinence. Further research will define the optimum selection criteria, dose, site of injection, re-injection frequency, and long-term results.
FUNDING: General Direction of Healthcare (French Ministry of Health).
The invention relates to a genipin cross-linked soybean protein based theophylline controlled-release gel preparation and a preparation method thereof. According to the invention, two different high-molecular compounds of soybean protein and chitosan, and a natural cross-linking agent genipin form a framework material of the gel preparation for controlling the releasing of theophylline. The preparation method of the gel preparation comprises steps that: soybean protein is dispersed in a sodium hydroxide solution; the mixture is heated and stirred until completely dissolved; the mixture and an acetic acid solution of chitosan are well mixed according to a certain proportion; theophylline is added to he mixture; a certain amount of an aqueous solution of genipin is added to the mixture for carrying out cross-linking; and a gel is formed through a thermostatic water bath. The surface of the gel preparation is smooth, and the gel is dark green and opaque. The inner part of the gel preparation is in a compact folded network structure. The gel preparation is characterized by no toxicity, stable three-dimensional network structure, good compatibility, and good dispersity. With the gel preparation, the stability of the active component is improved.